TY - JOUR
T1 - Lower cognitive performance in healthy G2019S LRRK2 mutation carriers
AU - Thaler, Avner
AU - Mirelman, Anat
AU - Gurevich, Tanya
AU - Simon, Ely
AU - Orr-Urtreger, Avi
AU - Marder, Karen
AU - Bressman, Susan
AU - Giladi, Nir
N1 - Funding Information:
Study funding: Supported by grants from the Tel Aviv Sourasky Medical Center Grant of Excellence, Khan Foundation, Israel Science Foundation Heritage Legacy, the Michael J. Fox Foundation for Parkinson's Research, and the UMC ST Radboud, Nijmegen, the Netherlands. The LRRK2 Ashkenazi Jewish Consortium is funded by the Michael J. Fox Foundation, New York, New York.
PY - 2012/9/4
Y1 - 2012/9/4
N2 - Objective: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene. Methods: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 ± 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale. Results: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007). Conclusion: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD.
AB - Objective: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene. Methods: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 ± 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale. Results: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007). Conclusion: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD.
UR - http://www.scopus.com/inward/record.url?scp=84866091335&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e3182684646
DO - 10.1212/WNL.0b013e3182684646
M3 - Article
AN - SCOPUS:84866091335
SN - 0028-3878
VL - 79
SP - 1027
EP - 1032
JO - Neurology
JF - Neurology
IS - 10
ER -